ALK-Abelló A/S (AKABY) Stock

About ALK-Abelló A/S

ALK-Abelló A/S operates as a global leader in allergy solutions, serving markets across Europe, North America, and internationally. The company provides a diverse range of allergy immunotherapy (AIT) products, offered as injections, sublingual drops, and tablets, specifically formulated to address common allergies like house dust mite, grass, tree pollen, ragweed, and Japanese cedar. In addition to these therapeutic options, ALK-Abelló manufactures adrenaline auto-injectors for emergency treatment of severe allergic reactions and produces diagnostic tools for allergy identification. Prominent products for allergic rhinitis include GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX. ACARIZAX, another key offering, targets both allergic rhinitis and allergic asthma. Established in 1923, ALK-Abelló A/S is headquartered in Hørsholm, Denmark.

the stock is valued at a price-to-earnings (P/E) ratio of 90.91, price-to-book of 8.11, price-to-sales of 8.12. Over the past 52 weeks the stock has ranged between $90.00 and $90.00, and currently trades at its 52-week high. It pays a dividend yielding 0.67%.

On profitability, ALK-Abelló A/S generates a return on equity (ROE) of 6.29%, return on capital employed of 22.33%, an operating margin of 7.71%, a net profit margin of 5.59%.

Official website: www.alk.net